Osteoporosis With Current Fragility Fracture Clinical Trial
Official title:
Secondary Prevention of Osteoporosis in Women Over 50 Years Old After Low Intensity Fracture of the Upper Limb: Evaluation of an Intervention Focused on the Patient.
Osteoporosis is a disease characterized by reduced bone mass and increased skeletal
fragility, predisposing to an increased fracture risk. The presence of a low trauma fracture
is a powerful predictor of future fractures and about 50% of patients with a fragility
fracture will suffer a subsequent fracture in the next 10 years (Center Jacqueline R, 2007).
Osteoporotic fractures are associated with an increased morbidity and mortality but also high
financial costs. However, less than 20% of patients presenting a low trauma fracture receive
an appropriate post-fracture osteoporosis management (Little and Eccles, 2010). The
hypothesis of a lack of information and an under assessment of consequences by both patients
and physicians has been raised to explain this gap between recommended care and usual
practices.
The aim of the PREVOST program is to assess the efficiency of patient-centered osteoporosis
prevention program, after a fragility fracture of the upper limb, to improve post-fracture
management of osteoporosis (ie BMD test and / or osteoporosis treatment) in women over 50
years old.
This open randomized controlled trial aims to compare the BMD or osteoporosis treatment
prescription rate at 6 months after inclusion between two groups: "intervention" receiving
information on fracture and osteoporosis (oral and written), phone call reminders and written
information to give to their family physician, and "control" receiving usual care without
information.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01745068 -
Partnership for Applied Research in Fracture Prevention Programs for the Elderly
|
N/A |